Luncheon Briefing Presentation
Monday, December 14 · 12:15 pm - 1:15 pm
Scaling Wet-Lab Validation for AI-based Biologic Discovery
Oren Beske, PhD | Head of Biologics at Twist Bioscience
Vanessa Braunstein | Sr. Director TuneLab AI Drug Discovery Platform at Eli Lilly and Company
As AI shifts antibody discovery from exploratory search to generative engineering, the key bottleneck is no longer computational design, but high-throughput, high-quality wet-lab data. This presentation highlights how Twist Bioscience’s silicon-based DNA synthesis powers an integrated antibody ecosystem. From discovery through data, Twist seamlessly translates in silico designs into rapid physical validation. To illustrate this ecosystem, Eli Lilly will join us to show how Lilly TuneLabs grants biotech innovators access to advanced AI models trained on Lilly’s research data. We will detail how Twist serves as a preferred wet-lab partner—generating standardized characterization data for developability models like AbLab and enabling seamless, automated ordering for TuneLab users to drive continuous, closed-loop model optimization.